ContraFect Corporation (CFRX) |
0.05 -0.019 (-27.95%) 12-05 15:31 |
Open: | 0.06 |
High: | 0.062 |
Low: | 0.0457 |
Volume: | 910,216 |
Market Cap: | 0(M) |
PE Ratio: | -0 |
Exchange: | NASDAQ Capital Market |
Industry: | Biotechnology |
Sector: | Healthcare |
Technical analysis | ||||
sell | buy |
Resistance 2: | 0.04 |
Resistance 1: | 0.03 |
Pivot price: | 0.03 |
Support 1: | 0.02 |
Support 2: | 0.02 |
52w High: | 9.616 |
52w Low: | 0.025 |
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia. The company also develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis; and CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also initiated an expanded access program to provide Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.
EPS | -10.830 |
Book Value | -0.540 |
PEG Ratio | 0.00 |
Gross Profit | 0.000 |
Profit Margin (%) | 0.00 |
Operating Margin (%) | 0.00 |
Return on Assets (ttm) | -117.4 |
Return on Equity (ttm) | 0.0 |
Mon, 16 Oct 2023
ContraFect Announces FDA Clearance of CF-370 IND Application to Proceed With Phase 1 Clinical Study - Yahoo Finance
Thu, 17 Aug 2023
CFRX: CF-370 IND to be Filed in 3Q23… - Yahoo Finance
Thu, 27 Apr 2023
What's Going On With ContraFecta Stock Today - Yahoo Finance
Tue, 18 Apr 2023
Contrafect Corporation CFRX is pretty much bust so why d the stock jump 154%? - Dhaka Tribune
Mon, 27 Feb 2023
3 Short Squeeze Penny Stocks To Watch After CFRX Stock Explodes - Penny Stocks
Fri, 27 Jan 2023
Why Is ContraFect (CFRX) Stock Down 23% Today? - InvestorPlace
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |